Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome

Kasapoglu U., Ruhi C., Tugcu M., Boynuegri B., Titiz I., Hancer V. S., ...More

ANNALS OF TRANSPLANTATION, vol.20, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20
  • Publication Date: 2015
  • Doi Number: 10.12659/aot.894665
  • Journal Name: ANNALS OF TRANSPLANTATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Complement C5, Hemolytic-Uremic Syndrome, Kidney Transplantation, CLINICAL PRESENTATION, COMPLEMENT MUTATIONS, RECURRENCE, IMPACT, RECIPIENTS, EFFICACY, SAFETY, GENES, HUS
  • Marmara University Affiliated: No

Abstract

Background: Atypical hemolytic uremic syndrome (aHUS) is a very rare disease, which presents with microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Progression to end-stage renal disease (ESRD) from acute kidney injury is observed in 60% of aHUS cases. The prognosis of aHUS patients who undergo kidney transplantation (Ktx) is generally poor, but these patients should be treated prophylactically with eculizumab to prevent recurrence after transplantation.